The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors ...

Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...